Clinical Trial Detail

NCT ID NCT02005289
Title Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications

prolymphocytic leukemia

CLL/SLL

chronic lymphocytic leukemia

Therapies

Lenalidomide + Tafasitamab-cxix

Ibrutinib + Tafasitamab-cxix

Age Groups: adult senior

No variant requirements are available.